For example, 4,5,6,7-tetrabromobenzotriazole (TBB), a selective CK2 inhibitor, has been reported to directly inhibit CSNK2B activity in vitro (Stengel et al. 2020), suggesting that it will be interesting to test whether TBB treatment can inhibit the biological functions of CSNK2B in CRC cells. Here, CSNK2B is linked to colorectal carcinoma.